Explore the Potential with AI-Driven Innovation
This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.
The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.
The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.
We utilise our cutting-edge, exclusive workflow to develop focused libraries.
Fig. 1. The sreening workflow of Receptor.AI
Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
Q9Y365
UPID:
STA10_HUMAN
Alternative names:
Antigen NY-CO-28; PCTP-like protein; Serologically defined colon cancer antigen 28; StAR-related lipid transfer protein 10
Alternative UPACC:
Q9Y365; O60532
Background:
START domain-containing protein 10, known by alternative names such as Antigen NY-CO-28 and Serologically defined colon cancer antigen 28, plays a crucial role in lipid metabolism. It specializes in the transfer of phospholipids, including phosphatidylcholine (PC) and phosphatidylethanolamine (PE), between membranes. This protein exhibits a preference for lipid species with specific acyl chain characteristics, highlighting its selective function in cellular lipid regulation.
Therapeutic significance:
Understanding the role of START domain-containing protein 10 could open doors to potential therapeutic strategies. Its involvement in lipid transfer and metabolism suggests a foundational role in cellular processes, which, if modulated, could offer new avenues for treating metabolic disorders.